Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases

Creative Commons License

GOOSSENS H., MALHOTRA-KUMAR S., ERAKSOY H., Unal S., grabein b., MASTERTON R., ...Daha Fazla

CLINICAL MICROBIOLOGY AND INFECTION, cilt.10, sa.8, ss.760-762, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 8
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1111/j.1469-0691.2004.00957.x
  • Dergi Adı: CLINICAL MICROBIOLOGY AND INFECTION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.760-762
  • Hacettepe Üniversitesi Adresli: Evet

Özet

An omnibus survey of microbiologists (n = 400) and a survey of participants (n = 49) in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme were conducted to determine the awareness and prevalence of extended-spectrum beta-lactamases (ESBLs), and the regularity and method of screening. Of the omnibus survey participants, 69% screened regularly for ESBLs, compared with 83% of MYSTIC participants. In both surveys, ESBLs were more common in Klebsiella pneumoniae (73% and 79%, respectively) and Escherichia coli (63% and 81%, respectively) than in other bacteria. The surveys demonstrated that awareness of, and testing for, ESBLs is inconsistent.